Q3 2025 Liquidia Corp Earnings Call Transcript
Key Points
- Liquidia Corp (LQDA) achieved profitability in its first full quarter following the launch of YUTREPIA, with positive adjusted EBITDA of $10.1 million.
- YUTREPIA has received over 2,000 unique prescriptions and initiated therapy for more than 1,500 patients, with a high referral-to-start ratio of 85%.
- The company reported $51.7 million in net product sales of YUTREPIA during the third quarter of 2025.
- Liquidia Corp (LQDA) has established contracts with the three largest commercial payers, enhancing market access for YUTREPIA.
- The company is exploring new clinical opportunities for YUTREPIA, including potential studies in IPF and PPF, which could expand its market reach.
- Liquidia Corp (LQDA) recorded a net loss of $3.6 million for the quarter, despite achieving positive adjusted EBITDA.
- The company faces ongoing litigation with United Therapeutics, which could impact future operations depending on the outcome.
- There is uncertainty regarding the timing and outcome of the legal decision, which could range from market removal to royalty payments.
- The company is still in the early phase of launch, which may lead to variability in ordering patterns and potential seasonality effects.
- Approximately 50% of new patients are using a 28-day voucher program, which may impact short-term revenue recognition.
Good morning, and welcome to the Liquidia Corporation third quarter 2025 financial results and corporate update conference call. My name is Carmen, and I will be your operator today. (Operator Instructions) Please note that today's call is being recorded.
I now turn the call over to Jason Adair, Chief Business Officer.
Thank you, Carmen, and good morning, everyone. It's my pleasure to welcome you to Liquidia's third quarter 2025 financial results and corporate update conference call. Joining me today are Dr. Roger Jeffs, Chief Executive Officer; Michael Kaseta, Chief Operating Officer and Chief Financial Officer; Dr. Rajeev Saggar, Chief Medical Officer; Scott Moomaw, Chief Commercial Officer; and Rusty Schundler, General Counsel.
Before we begin, please note that today's discussion will include forward-looking statements, including statements regarding future results, product performance and ongoing clinical or commercial activities. These statements are subject to risks and uncertainties
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
